एफाविरेंज़, लैमिवुडिन और टेनोफोविर और फोसएम्प्रेनाविर का इंटरैक्शन

Lactic Acidosis and Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals.

• SYMFI should not be administered with other antiretroviral medications for the treatment of HIV-1 infection.

Not Recommended with Other Antiretroviral Medications SYMFI is a complete regimen for the treatment of HIV-1 infection; therefore, it should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

Fosamprenavir calcium/ritonavir: ↑ Amprenavir ↓Delavirdine Non-nucleoside reverse transcriptase inhibitor: Efavirenz a Fosamprenavir calcium: ↓ Amprenavir Fosamprenavir calcium/ritonavir: ↓ Amprenavir Appropriate doses of the combinations with respect to safety and efficacy have not been established.

No change in the ritonavir dose is required when efavirenz is administered with Fosamprenavir calcium plus ritonavir twice daily.

Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of fosamprenavir calcium/ritonavir, respectively.

Coadministration of fosamprenavir calcium with drugs that induce CYP3A4 may decrease amprenavir (active metabolite) concentrations leading to potential loss of virologic activity.

Coadministration of fosamprenavir calcium and drugs that induce CYP3A4, such as rifampin, may decrease amprenavir concentrations and reduce its therapeutic effect.